Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + FOLFOX Neoadjuvant Chemoradiation in Rectal Cancer
NCT03921684Phase 2Active, not recruiting
- Start
- Apr 2019
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in rectal cancer. Primary endpoints: Pathological Complete Response Rate up to 24 months, Incidence of Treatment-Emergent Adverse Events up to 24 months and 1 more. Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03921684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921684.